Evaluation of Interethnic Differences in Repinotan Pharmacokinetics by Using Population Approach-Reference-Cited by-同舟云学术

Evaluation of Interethnic Differences in Repinotan Pharmacokinetics by Using Population Approach

Published:2006 Issue:1 Volume:21 Page:61-69
ISSN:1347-4367
Container-title:Drug Metabolism and Pharmacokinetics
language:en
Short-container-title:Drug Metabolism and Pharmacokinetics

Author:

Tanigawa Takahiko,Heinig Roland,Kuroki Yoshihiro,Higuchi Shun

Publisher

Japanese Society for the Study of Xenobiotics

Subject

Pharmacology (medical),Pharmaceutical Science,Pharmacology

Reference19 articles.

1. Neuroprotective effect of the novel 5-HT1A receptor agonist BAY×3702 in a rat model of permanent focal cerebral ischemia and traumatic brain injury;Horvath;Soc. Neurosci. Abstr.,1997

2. Neuroprotective effect of the novel 5-HT1A receptor agonist BAY×3702 in the rat model of acute subdural hematoma;Horvath;Neurotrauma Abstr.,1997

3. Pharmacodynamic effects of 5-HT1A agonists on pupil reaction. 21st AGNP Symposium in Nuremberg;Böttcher,1999

4. for the Traumatic Brain Injury Study Group: Repinotan (BAY ×3702): a 5HT1A agonist in traumatically brain injured patients;Ohman;J. Neurotrauma,2001

5. The BRAINS study: safety, tolerability, and dose-finding of repinotan in acute stroke;Teal;Can. J. Neurol. Sci.,2005

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inter‐ethnic differences in pharmacokinetics—is there more that unites than divides?;Pharmacology Research & Perspectives;2021-11-02

2. Evaluation of the estimation and classification performance of NONMEM when applying mixture model for drug clearance;CPT: Pharmacometrics & Systems Pharmacology;2021-10-24

3. The association between cigarette smoking and efavirenz plasma concentration using the population pharmacokinetic approach;British Journal of Clinical Pharmacology;2021-03-10

4. Development of visual predictive checks accounting for multimodal parameter distributions in mixture models;Journal of Pharmacokinetics and Pharmacodynamics;2019-04-09

5. Evaluation of the Impact of UGT Polymorphism on the Pharmacokinetics and Pharmacodynamics of the Novel PPAR Agonist Sipoglitazar;The Journal of Clinical Pharmacology;2013-01-24